Related Experiment Video
Updated: Apr 3, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Hemodialysis Using High Cut Off Filters in Light Chain Cast Nephropathy
Niels Henrik Buus1, Jesper Moesgaard Rantanen, Søren Palmelund Krag
1Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Insights
High cutoff (HCO) dialysis combined with bortezomib effectively restores kidney function in patients with light chain (LC) cast nephropathy. Greater reduction in LC levels during HCO dialysis correlates with improved renal recovery.
Area of Science:
- Nephrology
- Oncology
- Hematology
Background:
- Light chain (LC) cast nephropathy is a complication of monoclonal gammopathies.
- Acute kidney injury in these patients may benefit from renal replacement therapy.
- High cutoff (HCO) dialysis is a potential treatment to remove LCs.
Purpose of the Study:
- To evaluate the efficacy of HCO dialysis in improving renal function in patients with malignant monoclonal gammopathies and LC cast nephropathy.
Main Methods:
- Ten patients with LC cast nephropathy received HCO dialysis and bortezomib-based chemotherapy.
- Serum LC concentrations were measured pre- and post-dialysis.
- Plasma creatinine levels were monitored to assess renal function.
Main Results:
- Six patients achieved complete kidney function recovery, and three had partial recovery.
- Patients with greater LC reduction during HCO dialysis showed lower creatinine levels at 6 and 9 months.
- Compared to a historic control group, HCO dialysis demonstrated superior renal recovery rates.
Conclusions:
- HCO dialysis, in conjunction with bortezomib, promotes significant renal recovery in patients with LC cast nephropathy.
- The degree of LC reduction achieved during HCO dialysis is a key determinant of renal outcome.
Background/Aim:
Hemodialysis using high cutoff (HCO) filters possibly improves renal function in diseases with light chain (LC) overproduction and acute kidney injury. We established the effect of HCO dialysis on renal outcome in consecutive patients with malignant monoclonal gammopathies and LC cast nephropathy.
Methods:
LC concentration was measured before and after each dialysis session in 10 patients receiving HCO dialysis and bortezomib-based chemotherapy, and their renal function was monitored by plasma creatinine.
Results:
The number of HCO sessions ranged from 4 to 34 (mean 13). Six patients recovered kidney function, 3 regained partial function while 1 patient continued chronic dialysis. Patients with the largest reductions in LC during HCO treatments had the lowest creatinine at 6 and 9 months of follow-up. For comparison, only 2 out of 10 patients in a historic control group recovered kidney function.
Conclusion:
HCO dialysis combined with bortezomib results in good renal recovery with kidney function being dependent on the degree of LC lowering.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Dialysis
Acute Kidney Injury V: Interprofessional Care

